Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evonik Industries, a specialty chemicals company, has stepped up the pharmaceutical amino acid glycine production capacity by 50% to meet growing demand and solidify its market position.
Subscribe to our email newsletter
Besides being widely used in the production of pharmaceuticals, glycine is a component of infusion solutions and specialty nutrition items.
The Germany-based company is investing in a new plant at its Chinese Nanning site to add new products to its specialty chemical portfolio by milling and sieving processes.
Pharmaceutical amino acids marketing manager Jean-Louis Philippe said they are now able to provide glycine in all crystalline forms and particle size distributions requested by customers.
Rexim, the wholly owned subsidiary of Evonik, produces amino acids, peptides and amino acid derivatives, which are mainly used to manufacture active pharmaceutical ingredients for anti-hypertensive and diabetes drugs.
Last year Rexim has acquired Belgian Tessenderlo Group’s glycine business to further strengthen its presence in the market.